Event Brief
Pancreatic cancer drug shows early lung cancer promise
By The BriefBrief · Sources (1)
Filed: Sep 04, 2026 at 12:00 PM ET
Summary: An early-phase trial tested daraxonrasib, a pill approved for advanced pancreatic cancer, in 136 patients with non-small cell lung cancer. The drug was reported safe and reduced tumor burden in more than 30% of patients with RAS-protein mutations, according to a study published Wednesday in the New England Journal of Medicine.
WHO: Researchers and 136 patients with non-small cell lung cancer; study authors published in the New England Journal of Medicine
WHAT: Early clinical trial results suggest daraxonrasib may reduce tumors in a subset of non-small cell lung cancer patients with RAS-protein mutations.
WHEN: Sep 04, 2026 at 11:01 AM ET
WHERE: CA
WHY: Cause not yet established.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Lynwood Library reopens after major renovation
Lynwood
Sep 04, 2026 at 12:00 PM ET
🔒
Malibu bid to control public trails rejected
Malibu
Sep 04, 2026 at 12:00 PM ET
🔒
County readies El Niño response for heavy rains
El Nino
Sep 04, 2026 at 12:00 PM ET
🔒
John Boston revisits the art of postcards
Local Column
Sep 04, 2026 at 12:00 PM ET
🔒
